3 billion CFU · vegan · gluten-free · 30 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Lactobacillus fermentum CECT5716 (now reclassified as Limosilactobacillus fermentum CECT5716) is a probiotic strain originally isolated from human breast milk of healthy mothers 4 days postpartum. It is one of the few probiotics with a human milk origin, giving it natural affinity for infant gut colonisation and maternal breast tissue. It has been extensively studied in infants, lactating mothers and adults for immune and anti-infectious properties.
CECT5716 produces organic acids, hydrogen peroxide and bacteriocins that inhibit pathogens. It competitively excludes Staphylococcus aureus and other mastitis-causing bacteria from breast tissue. In infants, it stimulates IgA secretion, enhances mucosal barrier integrity and modulates Th1/Th2 immune balance. A 2012 RCT showed it reduced gastrointestinal infections by 46% and upper respiratory infections by 27% in infants. A 2015 RCT in lactating mothers showed it significantly reduced Staphylococcus load in breastmilk and breast pain scores.
Lactating mothers with breast pain or high Staphylococcus load in breastmilk. Parents seeking infant gut and immune support (via maternal supplementation or infant formula). Adults seeking immune support during cold/flu season. Those interested in human milk-derived probiotics with natural colonisation affinity.
Individuals with severe immunosuppression. Those with central venous catheters. Premature infants (consult paediatrician). People with artificial heart valves (rare endocarditis risk). Side effects: Generally well-tolerated. Mild GI adjustment in first week. No adverse effects reported in infant safety trials. As with all probiotics, immunocompromised individuals should consult a physician.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 21873895 (infant GI and URTI reduction RCT), PMID 26352805 (mastitis and breast pain RCT), PMID 22155106 (safety in infants 1–6 months), PMID 8305821 (2021 meta-analysis of GI infection prevention), PMID 37432320 (clinical potential review 2023)
SacredBod's longer take on Lactobacillus Fermentum CECT5716 — context the structured blocks above don't capture.
Lactobacillus fermentum CECT5716 (now reclassified as Limosilactobacillus fermentum CECT5716) is a probiotic strain originally isolated from human breast milk of healthy mothers 4 days postpartum. It is one of the few probiotics with a human milk origin, giving it natural affinity for infant gut colonisation and maternal breast tissue. It has been extensively studied in infants, lactating mothers and adults for immune and anti-infectious properties.
CECT5716 produces organic acids, hydrogen peroxide and bacteriocins that inhibit pathogens. It competitively excludes Staphylococcus aureus and other mastitis-causing bacteria from breast tissue. In infants, it stimulates IgA secretion, enhances mucosal barrier integrity and modulates Th1/Th2 immune balance. A 2012 RCT showed it reduced gastrointestinal infections by 46% and upper respiratory infections by 27% in infants. A 2015 RCT in lactating mothers showed it significantly reduced Staphylococcus load in breastmilk and breast pain scores.
Lactating mothers with breast pain or high Staphylococcus load in breastmilk. Parents seeking infant gut and immune support (via maternal supplementation or infant formula). Adults seeking immune support during cold/flu season. Those interested in human milk-derived probiotics with natural colonisation affinity.
Typical dose: 3 billion CFU per day
Form: capsules (30 count)
Best time: morning
With food: with-food
Expected onset: 2–4 weeks for immune benefits; 1–3 weeks for mastitis/lactation support
Cycling: No cycling required. Can be taken continuously.
Known side effects: Generally well-tolerated. Mild GI adjustment in first week. No adverse effects reported in infant safety trials. As with all probiotics, immunocompromised individuals should consult a physician.
Who should avoid: Individuals with severe immunosuppression. Those with central venous catheters. Premature infants (consult paediatrician). People with artificial heart valves (rare endocarditis risk).
Avoid combining with: Antibiotics (take 2 hours apart), Immunosuppressants, Antifungals
Lactobacillus Fermentum CECT5716 is available on Amazon India with varying brand quality. When selecting a probiotic, verify CFU count at expiry (not just at manufacture), strain specificity and refrigeration requirements. Indian brand preferences include Tata 1mg, ZEROHARM, Carbamide Forte, HealthKart, Jarrow Formulas, Now Foods, and Meibotan. Prices vary significantly; compare cost-per-CFU rather than capsule count alone.
Schedule status in India: Not a Schedule H drug; available as dietary supplement.
Key citations: PMID 21873895 (infant GI and URTI reduction RCT), PMID 26352805 (mastitis and breast pain RCT), PMID 22155106 (safety in infants 1–6 months), PMID 8305821 (2021 meta-analysis of GI infection prevention), PMID 37432320 (clinical potential review 2023)
Evidence grade: B — Multiple infant RCTs; lactation RCT; 2021 meta-analysis of 3 RCTs (n=435 infants)
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
